Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Jayasuriya D C (1985). Regulation of Pharmaceuticals in Developing Countries. (Geneva: World Health Organization),
Dunlop D (1967). The Assessment of the Safety of Drugs and the role of Government in their Control. J. Clin. Pharmacol. 1, 184–92
Medicines Act (1968). (London: Her Majesty’s Stationery Office)
Commission of the European Communities (1984). The Rufes Governing Medicaments in the European Community. (Luxembourg: Office for Official Publications of the European Communities)
Zbinden G (1981). Scope and Limitation of Animal Models for the Prediction of Human Toxicity. In Brown SS and Davies DS (eds). Organ-Directed Toxicity, pp. 3–7. (Oxford: Pergamon Press)
Fletcher A P (1978). Drug Safety Testing and Subsequent Clinical Experience. J. R. Soc. Med. 71, 693–6
Griffin J P (1983). Repeat-dose long-term toxicity studies. In Balls M, Riddell R J and Worden A N (eds). Animals and Alternatives in Toxicity Testing, pp. 98–103. (London: Academic Press)
Laurence D R, Maclean A and Weatherall M (1984). Safety Testing of New Drugs. (London: Academic Press)
Rawlins M D and Thompson J W (1985). Mechanisms of adverse drug reactions. In Davies D M (ed). Textbook of Adverse Drug Reactions pp. 12–38, (Oxford: Oxford University Press)
Royal Society Study Group (1983). Risk Assessment. (London: The Royal Society)
Rawlins M D (1987). Advantages and disadvantages of different techniques of post-marketing surveillance. In Mann R D (ed). Adverse Drug Reactions pp. 67–74. (Carnforth: Parthenon Publishing)
Rawlins M D (1988). Spontaneous reporting of adverse drug reactions I: the data. Br. J. Clin. Pharmacol. 26, 1–6
Rawlins M D (1988). Spontaneous reporting of adverse drug reactions II: uses. Br. J. Clin. Pharmacol. 26, 7–12
Grahame-Smith D G (1987). Adverse drug reaction monitoring: the way forward. In Mann R D (ed). Adverse Drug Reactions pp. 201–14. (Carnforth: Parthenon Publishing)
Dukes G (1985). The Effect of Drug Regulation. (Lancaster: MTP Press)
Medewar C (1987). Observations on the UK Government’s 1987 Study of Control of Medicines. (London: Social Audit)
Green D G (1987). Medicines in the Marketplace. (London: IEA Health Unit)
Rawlins M D (1988). Drug regulation: evolution or revolution? Br. Med. J., 296, 379–80
Rawlins M D (1984). Doctors and the drug makers, Lancet, 2, 276–8
Office of Health Economics (1986). Crisis in Research. (London: Office of Health Economics)
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Kluwer Academic Publishers
About this chapter
Cite this chapter
Rawlins, M.D. (1989). Objectives and achievements of medicines regulation in the UK. In: Walker, S.R., Griffin, J.P. (eds) International Medicines Regulations. CMR Workshop Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-0857-4_9
Download citation
DOI: https://doi.org/10.1007/978-94-009-0857-4_9
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-6873-4
Online ISBN: 978-94-009-0857-4
eBook Packages: Springer Book Archive